Record 2025 Revenue and Margin Expansion Define Hinge Health’s Momentum
Hinge Health’s fourth quarter and full-year 2025 results confirm the company is hitting its stride, delivering standout growth across nearly every metric. With quarterly revenue up 46% year-over-year to $170.7 million and non-GAAP operating profits more than doubling, the digital musculoskeletal care provider’s financial trajectory looks increasingly robust.
CEO Daniel Perez underscored the significance of this acceleration, noting both the highest win rates and the largest number of eligible lives added in company history. “Our commercial momentum, combined with expanding margins and strong cash generation, gives us confidence to sustain leadership and drive attractive growth in 2026,” Perez emphasized.
Non-GAAP Profitability and Cash Flow Mark Major Milestones
Perhaps the most compelling data point is Hinge Health’s 124% year-over-year growth in non-GAAP income from operations in Q4, reaching $48.0 million. Full-year non-GAAP operating profit swung positive to $119.5 million from a loss in 2024, highlighting not only top-line growth but significant strides in operational efficiency. Non-GAAP gross margin reached 85% in Q4—up from 82%—while quarterly free cash flow surged 65% to $61.5 million.
| Key Metric | Q4 2025 | Q4 2024 | Full Year 2025 | Full Year 2024 |
|---|---|---|---|---|
| Revenue ($M) | 170.7 | 117.3 | 587.9 | 390.4 |
| Non-GAAP Gross Margin (%) | 85 | 82 | 83 | 78 |
| Non-GAAP Op. Income ($M) | 48.0 | 21.4 | 119.5 | -26.1 |
| Free Cash Flow ($M) | 61.5 | 37.3 | 179.6 | 45.2 |
Client and Member Metrics Reach New Highs
Growth isn’t limited to the income statement. The number of clients rose 25% year-over-year to 2,830, while the number of contracted lives increased to 25 million, up from 20 million a year ago. Hinge Health’s member base surged 47% to 782,890, and LTM (last twelve months) average eligible lives climbed 28% to 20.1 million. The annual yield—the ratio of active members to eligible lives—reached 3.9%, a 50-basis-point improvement.
| Metric | 2025 | 2024 | Y/Y Change |
|---|---|---|---|
| Clients | 2,830 | 2,256 | +25% |
| Contracted Lives (M) | 25.0 | 20.0 | +25% |
| Members | 782,890 | 532,326 | +47% |
| LTM Avg. Eligible Lives (M) | 20.1 | 15.7 | +28% |
| Annual Yield (%) | 3.9 | 3.4 | +0.5 |
2026 Guidance Signals Continued Outperformance
Hinge Health’s 2026 guidance further supports a bullish view. For Q1 2026, revenue is projected at $171–$173 million (year-over-year growth of 39%), with non-GAAP operating income seen rising 108% at the midpoint. Full-year revenue guidance ranges from $732 million to $742 million—up 25%—with operating margins targeted at 21%.
| 2026 Outlook | Low | High | Midpoint Y/Y % |
|---|---|---|---|
| Revenue ($M) | 732 | 742 | +25% |
| Non-GAAP Op. Income ($M) | 151 | 156 | +29% |
| Non-GAAP Op. Margin (%) | 21 | 21 | - |
Share Repurchase Program Underscores Financial Strength
In a further sign of confidence, Hinge Health’s board authorized a $250 million share repurchase program in November 2025, with $65 million already completed in Q4. With nearly $479 million in total cash and marketable securities, the company is well-positioned to fund growth initiatives while returning capital to shareholders.
Key Takeaways: Operational Leverage Drives Bullish Outlook
Hinge Health is showing the hallmarks of a business moving from growth to sustained profitability. Revenue growth remains strong, margins are expanding, and key engagement metrics are at all-time highs. The ambitious 2026 targets—paired with a robust balance sheet and share buybacks—position the company as an emerging leader in digital health. Investors will want to watch the upcoming earnings webcast for management’s color on product innovation and further market expansion.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI